Skip to main content
. 2023 Aug 2;129(6):925–934. doi: 10.1038/s41416-023-02369-w

Fig. 4. PD-L1-positive I-sEVs did not suppress T cells in vitro.

Fig. 4

a Confocal microscopy analysis of activated Jurkat T cells after incubation with CFSE-labeled T-sEVs (CAL27, H1975) or stimulated I-sEVs (Raji, THP-1). b Representative contour plots of Ki-67 expression in activated Jurkat T cells after treatment with sEVs. c The proportions of Ki-67-positive Jurkat T cells in (b). d IFN-γ released by activated Jurkat T cells after treatment with sEVs as measured by ELISA. e Western blot analysis of Akt, p-Akt, ERK and p-ERK levels in T cells treated with sEVs. All lanes were loaded with the same amount of total protein. f High-resolution flow cytometry of soluble PD-1-Fc protein binding to tumor cell- or immune cell-derived sEVs. The soluble PD-1 Fc protein was stained with Fc-PE immunofluorescent antibody. Data are mean ± SD of three independent experiments (c, d, f). P values are from one-way ANOVA test (c, d) and two-sided unpaired t test (f).